New study finds enzyme linked to rare immune disorder could be key to treatment

2 min read

In the intricate dance of immune cell differentiation, researchers have long sought to understand the molecular underpinnings governing the unique characteristics of T helper 17 (T H 17) lineage cells. These canonical transcriptional factors play a pivotal role in autoimmune disease pathogenesis, with T H 17 cells implicated in various inflammatory conditions affecting both mice and humans.

Su Y et al.'s recent study sheds light on this critical process by identifying a novel regulator of T H 17 differentiation: Dhx9, a nuclear helicase. Conditional deletion of Dhx9 in T cells resulted in reduced T H 17 differentiation and improved symptoms in mouse models of experimental autoimmune encephalomyelitis (EAE) and rheumatoid arthritis (RA). Furthermore, the researchers discovered Nono as an uncharacterized regulator that interacts with Dhx9 to modulate T H 17 cell fate. This intricate interplay highlights the complex interplay between signaling pathways in immune cell development.

The IL-6-STAT3 signaling pathway also emerged as a critical driver of T H 17 cell differentiation, promoting the up-regulation of Dhx9 expression. Moreover, the researchers identified punicalagin, a small-molecule inhibitor of Dhx9, which effectively suppressed T H 17 differentiation and EAE progression. These findings provide a mechanistic understanding of T H 17 lineage commitment and underscore the therapeutic potential for autoimmune disease intervention.

As we contemplate the intricate mechanisms governing immune cell differentiation, it's striking to consider how these processes reflect broader principles at play in the universe. The precise orchestration of transcriptional programs, like the balance between Dhx9 and Nono expression, echoes the intricate dance of celestial mechanics governing planetary orbits. Similarly, the human immune system's remarkable capacity for both cooperation and dysregulation resonates with the complex interplay between order and chaos that pervades our cosmos. By unraveling the molecular mysteries underlying autoimmune disease, we are reminded of the profound interconnectedness of life and the universe itself.

1 min read

In a breakthrough discovery, researchers have shed light on the mysterious world of T helper 17 (TH17) lineage differentiation. For years, scientists have known that TH17 cells play a pivotal role in autoimmune diseases, but the precise mechanisms behind their formation had remained unclear. Now, a team led by Su Y has identified Dhx9, a nuclear helicase, as a key player in this process.

It turns out that Dhx9 is positively correlated with TH17 lineage during the progression of autoimmune diseases. When Dhx9 was conditionally deleted in T cells, it significantly reduced TH17 differentiation and improved symptoms in mouse models of experimental autoimmune encephalomyelitis (EAE) and rheumatoid arthritis (RA). This finding raises hopes for new treatments for these devastating diseases.

But how does Dhx9 work its magic? Researchers found that IL-6 signaling promotes TH17 cell differentiation by up-regulating Dhx9 expression. And, in a surprise discovery, punicalagin - a small molecule inhibitor of Dhx9 - effectively suppressed TH17 differentiation and EAE progression. These findings not only illuminate the mysteries of TH17 lineage but also offer new avenues for treating autoimmune diseases.

1 min read

In the body's own immune response, there are tiny sparks that help decide which cells will turn on and which won't. For T helper 17 cells, these sparks come from a special enzyme called Dhx9. When researchers looked at mice with autoimmune diseases, they found that Dhx9 was always present when these cells were forming.

Removing or blocking Dhx9 completely stopped the formation of these problematic cells in mouse models of disease. This led to better symptoms and even reversed some damage. The team also discovered a small molecule that could suppress Dhx9's activity, which showed promise as a potential treatment for autoimmune diseases like rheumatoid arthritis and experimental autoimmune encephalomyelitis.